<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">cardio</journal-id><journal-title-group><journal-title xml:lang="ru">Кардиология</journal-title><trans-title-group xml:lang="en"><trans-title>Kardiologiia</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">0022-9040</issn><issn pub-type="epub">2412-5660</issn><publisher><publisher-name>Kardiomag</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.18087/cardio.2019.10.n520</article-id><article-id custom-type="elpub" pub-id-type="custom">cardio-520</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>АТЕРОСКЛЕРОЗ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ATHEROSCLEROSIS</subject></subj-group></article-categories><title-group><article-title>Взаимосвязь концентрации липопротеида(а) и показателей воспаления с мультифокальным атеросклерозом у женщин</article-title><trans-title-group xml:lang="en"><trans-title>The Relationship of the Concentration of Lipoprotein(a) and Markers of Inflammation with Multifocal Atherosclerosis in Women</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-8909-8662</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Афанасьева</surname><given-names>О. И.</given-names></name><name name-style="western" xml:lang="en"><surname>Afanasieva</surname><given-names>O. I.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Ольга Ильинична Афанасьева – доктор биологических наук, ведущий научный сотрудник лаборатории проблем атеросклероза института экспериментальной кардиологии  ФГБУ «НМИЦК» МЗ РФ.</p><p>Москва</p><p>SPIN-код: 3728-2306</p></bio><bio xml:lang="en"><p>Olga Ilyinichna Afanasieva - Ph.D., Dr.Sci., Leading Researcher of the laboratory of problems of atherosclerosis Institute of Experimental Cardiology.</p><p>Moscow</p></bio><email xlink:type="simple">Afanasieva@cardio.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-3617-9343</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Тмоян</surname><given-names>Н. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Tmoyan</surname><given-names>N. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Нарек Арамаисович Тмоян - младший научный сотрудник лаборатории нарушений липидного обмена НИИ клинической кардиологии ФГБУ «НМИЦК» МЗ РФ.</p><p>Москва</p><p>SPIN-код: 2952-1844</p></bio><bio xml:lang="en"><p>Narek Aramaisovich Tmoyan - Junior researcher of Laboratory of Lipid Disorders.Moscow</p></bio><email xlink:type="simple">ntmoyan@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-0682-8699</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Клесарева</surname><given-names>Е. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Klesareva</surname><given-names>E. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Елена Александровна Клесарева – кандидит технических наук, научный сотрудник лаборатории проблем атеросклероза института экспериментальной кардиологии  ФГБУ «НМИЦК» МЗ РФ.</p><p>Москва</p><p>SPIN-код: 5659-8042</p></bio><bio xml:lang="en"><p>Elena Aleksandrovna Klesareva - Researcher of the laboratory of problems of atherosclerosis Institute of Experimental Cardiology.</p><p>Moscow</p></bio><email xlink:type="simple">hea@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-1132-2529</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Разова</surname><given-names>О. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Razova</surname><given-names>O. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Оксана Андреевна Разова - научный сотрудник лаборатории проблем атеросклероза института экспериментальной кардиологии ФГБУ «НМИЦК» МЗ РФ.</p><p>Москва</p><p>SPIN-код: 6140-8830</p></bio><bio xml:lang="en"><p>Oksana Andreevna Razova - Researcher of the laboratory of problems of atherosclerosis Institute of Experimental Cardiology.</p><p>Moscow</p></bio><email xlink:type="simple">oarazova@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-1518-6552</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Ежов</surname><given-names>М. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Ezhov</surname><given-names>M. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Марат Владиславович Ежов - доктор медицинских наук, главный научный сотрудник лаборатории нарушений липидного обмена НИИ клинической кардиологии ФГБУ «НМИЦК» МЗ РФ.</p><p>Москва</p><p>SPIN-код: 7623-2135</p></bio><bio xml:lang="en"><p>Marat Vladislavovich Ezhov - Main Researcher, Head of Laboratory of Lipid Disorders.</p><p>Moscow</p></bio><email xlink:type="simple">marat_ezhov@mail.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-5725-3805</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Афанасьева</surname><given-names>М. И.</given-names></name><name name-style="western" xml:lang="en"><surname>Afanasieva</surname><given-names>M. I.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Марина Ильинична Афанасьева - научный сотрудник лаборатории проблем атеросклероза института экспериментальной кардиологии ФГБУ «НМИЦК» МЗ РФ.</p><p>Москва</p><p>SPIN-код: 6360-8846</p></bio><bio xml:lang="en"><p>Elena Aleksandrovna Klesareva - Researcher of the laboratory of problems of atherosclerosis.</p><p>Moscow</p></bio><email xlink:type="simple">afanasievabiocomerts@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-5944-6427</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Покровский</surname><given-names>С. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Pokrovsky</surname><given-names>S. N.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Сергей Николаевич Покровский - профессор, доктор биологических наук, главный научный сотрудник, И.О. руководителя лаборатории проблем атеросклероза  ФГБУ «НМИЦК» МЗ РФ.</p><p>Москва</p><p>SPIN-код: 8241-4146</p><p> </p></bio><bio xml:lang="en"><p>Sergei Nikolaevich Pokrovsky - Dr.Sci., professor, Head of the laboratory of problems of atherosclerosis, Institute of Experimental Cardiology.</p><p>Moscow</p></bio><email xlink:type="simple">dr.pokrovsky@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБУ «Национальный медицинский исследовательский центр кардиологии» Минздрава России</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Institute of Experimental Cardiology, National Medical Research Center for Cardiology</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>ФГБУ «Национальный медицинский исследовательский центр кардиологии» Минздрава России</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Myasnikov's Institute of Clinical Cardiology, National Medical Research Center for Cardiology</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2019</year></pub-date><pub-date pub-type="epub"><day>14</day><month>10</month><year>2019</year></pub-date><volume>59</volume><issue>10</issue><fpage>39</fpage><lpage>48</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Kardiomag, 2019</copyright-statement><copyright-year>2019</copyright-year><copyright-holder xml:lang="ru">Kardiomag</copyright-holder><copyright-holder xml:lang="en">Kardiomag</copyright-holder><license xlink:href="https://cardio.elpub.ru/jour/about/submissions#copyrightNotice" xlink:type="simple"><license-p>https://cardio.elpub.ru/jour/about/submissions#copyrightNotice</license-p></license></permissions><self-uri xlink:href="https://cardio.elpub.ru/jour/article/view/520">https://cardio.elpub.ru/jour/article/view/520</self-uri><abstract><sec><title>Цель исследования</title><p>Цель исследования. Изучение связи концентрации липопротеида(а) [Лп(а)], показателей системного воспаления и гуморального иммунитета с тяжестью атеросклеротического поражения различных сосудистых бассейнов у женщин.</p></sec><sec><title>Материалы и методы</title><p>Материалы и методы. В исследование были включены 148 женщин в возрасте 69±11 лет с результатами инструментального обследования коронарных, сонных и артерий нижних конечностей. Больные с гемодинамически значимыми, более 50%, атеросклеротическими поражениями, по данным коронарографии и ультразвукового исследования, в любом из трех указанных сосудистых бассейнов составили группу со стенозиру-ющим атеросклерозом, женщины без гемодинамически значимых стенозов в коронарном и периферических бассейнах - контрольную группу. В зависимости от обширности атеросклеротических поражений больные были разделены на подгруппы. В 1-я подгруппу были включены больные со стенозирующим атеросклерозом в одном сосудистом бассейне (n=44). Больные со стенозирующим мультифокальным атеросклерозом (поражение 2 сосудистых бассейнов и более) составили 2-я подгруппу (n=64). Контрольную группу составили 40 пациентов без стенозирующего атеросклероза в любом из сосудистых бассейнов. Все пациентки в исследуемых группах и 78% из контрольной группы принимали статины. У всех пациенток определены липидный состав крови, концентрация Лп(а), С-реактивный белок (СРБ). Препараты окисленных липопротеидов [окЛп(а)] получали Си2+-индуцированным свободно-радикальным окислением при температуре 37 °С в течение 3 ч. Титр аутоантител к Лп(а), липопротеиды низкой плотности (ЛНП) и их окисленным модификациям был определен методом твердофазного иммуноферментного анализа (ИФА). Концентрацию холестерина (ХС) ЛНП корригированного (ХС ЛНПкорр.) с поправкой на ХС, входящий в состав Лп(а), рассчитывали по формуле Фридвальда в модификации Dahlen: ХС ЛНПкорр. = ХС ЛНП - 0,3-Лп(а), мг/дл.</p></sec><sec><title>Результаты</title><p>Результаты. У 60 (80%) из 74 женщин с концентрацией Лп(а) выше 33 мг/дл (выше медианы распределения) диагностирован стенозирующий атеросклероз, при этом у 38 из них - мультифокальный. Увеличение концентрации Лп(а) в сыворотке крови ассоциировалось с наличием как изолированного стенозирующего, так и мультифокального атеросклероза, согласно данным одно-, многофакторного и логистического анализов, вне зависимости от других факторов риска и показателей воспаления. По результатам логистического регрессионного анализа, увеличение концентрации Лп(а) на 1 мг/дл повышало вероятность возникновения и развития мультифокального атеросклероза у женщин на 1%. При этом низкий уровень аутоантител класса IgM против Лп(а) был связан с выявлением стенозирующего атеросклероза в любом из трех сосудистых бассейнов с отношением шансов 7,6 (при 95 % доверительном интервале от 1,9 до 29,4; р=0,004 при сравнении пациенток с уровнем аутоантител класса IgM против Лп(а) из 1-го и 4-го квартилей) и обладал диагностической значимостью. Показатели системного воспаления, такие как СРБ и циркулирующие иммунные комплексы, были выше и обладали диагностической значимостью при выявлении мультифокального атеросклероза у обследованных женщин. Однако ни один из этих показателей не являлся предиктором возникновения стенозирующего атеросклероза по данным логистического регрессионного анализа.</p></sec><sec><title>Заключение</title><p>Заключение. Повышенная концентрация Лп(а) является независимым предиктором риска развития стенозирующего атеросклероза различных сосудистых бассейнов и возникновения мультифокального атеросклероза вне зависимости от других факторов риска, показателей системного воспаления и факторов гуморального иммунитета у женщин. Маркеры воспаления, а также аутоантитела класса IgM против Лп(а) обладают диагностической ценностью для выявления больных со стенозирующим поражением одного или нескольких сосудистых бассейнов.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Purpose</title><p>Purpose: to study relationship of lipoprotein(a) [Lp(a)], indicators of systemic inflammation and humoral immunity with severity of atherosclerotic involvement of various vascular beds in women.</p></sec><sec><title>Materials and methods</title><p>Materials and methods. We included in this study 148 women aged 69±11 years with results of instrumental investigation of coronary, carotid arteries, and arteries of lower extremities. According to results of coronary angiography and ultrasound study patients were distributed into two groups: with stenosing atherosclerosis (those with hemodynamically significant [&gt;50%] atherosclerotic lesions in any of these vascular beds, n=108), and control (those without hemodynamically significant stenoses, n=40). In dependence of extent of atherosclerotic involvement patients with stenosing atherosclerosis were divided into subgroups: with lesions in one vascular bed (subgroup 1, n=44) and with lesions in two and more vascular beds (subgroup 2, n=64). All patients with stenosing atherosclerosis and 78% of control patients took statins. In all patients we measured lipid spectrum, Lp(a) concentration, C-reactive protein (CRP). Preparations of oxidized lipoproteins [oxLp(a)] were obtained by Cu2+-induced free radical oxidation at 37 °С for 3 hours. Titer of autoantibodies to Lp(a), LDL and their oxidized modifications was determined by enzyme-linked immunosorbent assay (ELISA). Concentration of low-density lipoprotein cholesterol corrected on cholesterol in Lp(a) (LDLCh corr) was calculated by Dahlen modification of Friedewald formula.</p></sec><sec><title>Results</title><p>Results. Stenosing atherosclerosis was diagnosed in 60 of 74 women (80%) with Lp(a) concentration above median - 33 mg/dl (in 38 multifical). Increase of blood serum Lp(a) concentration was associated with presence of isolated as well as multifocal atherosclerosis according to unifactorial, multifactorial, and logistic analysis, irrespective of other factors of risk and indicators of inflammation. According to results of logistic regression analysis increase of Lp(a) concentration by 1 mg/dl was associated with 1 % elevation of probability of appearance and development of multifocal atherosclerosis in women. Low level of class IgM autoantibodies to Lp(a) was linked with detection of stenosing atherosclerosis in any of 3 vascular beds (1st vs. 4th quartile of IgM autoantibodies concentration - OR 7.6., 95%CI 1.9-29.4; р=0.004) and had diagnostic significance. Indicators of systemic inflammation such as CRP and circulating immune complexes were high and had diagnostic significance for detection of multifocal atherosclerosis in studied women. However none of indicators was predictor of appearance of stenosing atherosclerosis according to data of logistic regression analysis.</p></sec><sec><title>Conclusion</title><p>Conclusion. Elevated concentration of Lp(a) is an independent predictor of risk of development stenosing atherosclerosis in various vascular beds and appearance of multifocal irrespective of other risk factors, indicators of systemic inflammation, and factors of humoral immunity in women. Markers of inflammation, as well as IgM autoantibodies against Lp(a) have diagnostic value for detection of patients stenosing lesions ib one or several vascular beds.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>атеросклероз</kwd><kwd>липопротеид(а)</kwd><kwd>аутоантитела</kwd><kwd>иммуноглобулины М</kwd><kwd>стеноз сонных артерий</kwd><kwd>периферический атеросклероз</kwd><kwd>циркулирующие иммунные комплексы</kwd><kwd>системное воспаление</kwd><kwd>гуморальный иммунитет</kwd></kwd-group><kwd-group xml:lang="en"><kwd>atherosclerosis</kwd><kwd>lipoprotein (a)</kwd><kwd>autoantibodies</kwd><kwd>immunoglobulins M</kwd><kwd>carotid artery stenosis</kwd><kwd>peripheral atherosclerosis</kwd><kwd>circulating immune complexes</kwd><kwd>systemic inflammation</kwd><kwd>humoral immunity</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Aboyans V, Ricco J-B, Bartelink M-LEL, Bjorck M, Brodmann M, Cohnert T et al. Editor's Choice - 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS). European Journal of Vascular and Endovascular Surgery. 2018;55(3):305-68. DOI: 10.1016/j.ejvs.2017.07.018</mixed-citation><mixed-citation xml:lang="en">Aboyans V, Ricco J-B, Bartelink M-LEL, Bjorck M, Brodmann M, Cohnert T et al. Editor's Choice - 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS). European Journal of Vascular and Endovascular Surgery. 2018;55(3):305-68. DOI: 10.1016/j.ejvs.2017.07.018</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Ежов М.В., Сергиенко И.В., Аронов Д.М., Арабидзе Г.Г., Ахмеджанов Н.М., Бажан С.С. и др. Диагностика и коррекция нарушений липидного обмена с целью профилактики и лечения атеросклероза. Российские рекомендации VI пересмотр. Атеросклероз и дислипидемии. 2017;3:5-22</mixed-citation><mixed-citation xml:lang="en">Ezhov M.V., Sergienko I.V., Aronov D.M., Arabidze G.G., Akhmedzhanov N. M., Bazhan S.S. et al. Diagnostics and correction of lipid metabolism disorders for the prevention and treatment of atherosclerosis. Russian recommendations VI revision. Atherosclerosis and Dyslipidemias. 2017;3:5-22.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Libby P, Loscalzo J, Ridker PM, Farkouh ME, Hsue PY, Fuster V et al. Inflammation, Immunity, and Infection in Atherothrombosis. Journal of the American College of Cardiology. 2018;72(17):2071-81. DOI: 10.1016/j.jacc.2018.08.1043</mixed-citation><mixed-citation xml:lang="en">Libby P, Loscalzo J, Ridker PM, Farkouh ME, Hsue PY, Fuster V et al. Inflammation, Immunity, and Infection in Atherothrombosis. Journal of the American College of Cardiology. 2018;72(17):2071-81. DOI: 10.1016/j.jacc.2018.08.1043</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Avan A, Tavakoly Sany SB, Ghayour-Mobarhan M, Rahimi HR, Tajfard M, Ferns G. Serum C-reactive protein in the prediction of cardiovascular diseases: Overview of the latest clinical studies and public health practice. Journal of Cellular Physiology. 2018;233(11):8508-25. DOI: 10.1002/jcp.26791</mixed-citation><mixed-citation xml:lang="en">Avan A, Tavakoly Sany SB, Ghayour-Mobarhan M, Rahimi HR, Tajfard M, Ferns G. Serum C-reactive protein in the prediction of cardiovascular diseases: Overview of the latest clinical studies and public health practice. Journal of Cellular Physiology. 2018;233(11):8508-25. DOI: 10.1002/jcp.26791</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Weber C, Zernecke A, Libby P. The multifaceted contributions of leukocyte subsets to atherosclerosis: lessons from mouse models. Nature Reviews Immunology. 2008;8(10):802-15. DOI: 10.1038/nri2415</mixed-citation><mixed-citation xml:lang="en">Weber C, Zernecke A, Libby P. The multifaceted contributions of leukocyte subsets to atherosclerosis: lessons from mouse models. Nature Reviews Immunology. 2008;8(10):802-15. DOI: 10.1038/nri2415</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Azab B, Zaher M, Weiserbs KF, Torbey E, Lacossiere K, Gaddam S et al. Usefulness of Neutrophil to Lymphocyte Ratio in Predicting Short- and Long-Term Mortality After Non-ST-Elevation Myocardial Infarction. The American Journal of Cardiology. 2010;106(4):470-6. DOI: 10.1016/j.amjcard.2010.03.062</mixed-citation><mixed-citation xml:lang="en">Azab B, Zaher M, Weiserbs KF, Torbey E, Lacossiere K, Gaddam S et al. Usefulness of Neutrophil to Lymphocyte Ratio in Predicting Short- and Long-Term Mortality After Non-ST-Elevation Myocardial Infarction. The American Journal of Cardiology. 2010;106(4):470-6. DOI: 10.1016/j.amjcard.2010.03.062</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Nordestgaard BG, Langsted A. Lipoprotein (a) as a cause of cardiovascular disease: insights from epidemiology, genetics, and biology. Journal of Lipid Research. 2016;57(11):1953-75. DOI: 10.1194/jlr.R071233</mixed-citation><mixed-citation xml:lang="en">Nordestgaard BG, Langsted A. Lipoprotein (a) as a cause of cardiovascular disease: insights from epidemiology, genetics, and biology. Journal of Lipid Research. 2016;57(11):1953-75. DOI: 10.1194/jlr.R071233</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Burgess S, Ference BA, StaleyJR, Freitag DF, Mason AM, Nielsen SF et al. Association of LPA Variants With Risk of Coronary Disease and the Implications for Lipoprotein(a)-Lowering Therapies: A Mendelian Randomization Analysis. JAMA Cardiology. 2018;3(7):619-27. DOI: 10.1001/jamacardio.2018.1470</mixed-citation><mixed-citation xml:lang="en">Burgess S, Ference BA, StaleyJR, Freitag DF, Mason AM, Nielsen SF et al. Association of LPA Variants With Risk of Coronary Disease and the Implications for Lipoprotein(a)-Lowering Therapies: A Mendelian Randomization Analysis. JAMA Cardiology. 2018;3(7):619-27. DOI: 10.1001/jamacardio.2018.1470</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Orso E, Schmitz G. Lipoprotein (a) and its role in inflammation, atherosclerosis and malignancies. Clinical Research in Cardiology Supplements. 2017;12(S1):31-7. DOI: 10.1007/s11789-017-0084-1</mixed-citation><mixed-citation xml:lang="en">Orso E, Schmitz G. Lipoprotein (a) and its role in inflammation, atherosclerosis and malignancies. Clinical Research in Cardiology Supplements. 2017;12(S1):31-7. DOI: 10.1007/s11789-017-0084-1</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Афанасьева О.И., Ежов М.В., Сафарова М.С., Афанасьева М.И., Адамова И.Ю., Покровский С.Н. Полиморфизм липопротеида(а) как фактор риска коронарного и каротидного атеросклероза и его осложнений у женщин. Кардиоваскулярная терапия и профилактика. 2010;9(6):10-6</mixed-citation><mixed-citation xml:lang="en">Afanas'eva O.I., Ezhov M.V., Safarova M.S., Afanas'eva M.I., Adamova I.Yu., Pokrovsky S.N. Lipoprotein(a) polymorphism as a risk factor of coronary and carotid atherosclerosis and its complications in women. Cardiovascular Therapy and Prevention. 2010;9(6):10-6.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Ежов М.В., Афанасьева О.И., Беневоленская Г.Ф., Савченко А.П., Балахонова Т.В., Лякишев А.А., Покровский С.Н. Связь липопротеида(а) и фенотипа апобелка(а) с атеросклерозом у мужчин с ишемической болезнью сердца. Терапевтический архив. 2000;72(1):28-32</mixed-citation><mixed-citation xml:lang="en">Ezhov M.V., Afanas'eva O.I., Benevolenskaia G.F., Savchenko A.P., Balakhonova TV., Liakishev A.A. et al. Association oflipoprotein(a) and apolipoprotein(a) phenotypes with coronary and carotid atherosclerosis in CHD men. Therapeutic Archive. 2000;72(1):28-32.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Dahlen GH. Incidence of Lp(a) lipoprotein among populations. In: In: Scanu AM (ed). Lipoprotein(a).-San Diego: Academic Press;</mixed-citation><mixed-citation xml:lang="en">Dahlen GH. Incidence of Lp(a) lipoprotein among populations. In: In: Scanu AM (ed). Lipoprotein(a).-San Diego: Academic Press;</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Афанасьева О.И., Адамова И.Ю., Беневоленская Г.Ф., Покровский С.Н. Иммуноферментный метод определения липопротеида(а). Бюллетень экспериментальной биологии и медицины. 1995;120(4):1030-3. DOI: 10.1007/BF02444976</mixed-citation><mixed-citation xml:lang="en">Afanas'eva O.I., Adamova I.Yu., Benevolenskaya G.F., Pokrovskiy S.N. Enzyme immunoassay of lipoprotein(a). Bulletin of Experimental Biology and Medicine. 1995;120(4):1030-3. DOI: 10.1007/BF02444976</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Cho KI, Cho SH, Her A-Y, Singh GB, Shin E-S. Prognostic Utility of Neutrophil-to-Lymphocyte Ratio on Adverse Clinical Outcomes in Patients with Severe Calcific Aortic Stenosis. PLOS ONE. 2016;11(8):e0161530. DOI: 10.1371/journal.pone.0161530</mixed-citation><mixed-citation xml:lang="en">Cho KI, Cho SH, Her A-Y, Singh GB, Shin E-S. Prognostic Utility of Neutrophil-to-Lymphocyte Ratio on Adverse Clinical Outcomes in Patients with Severe Calcific Aortic Stenosis. PLOS ONE. 2016;11(8):e0161530. DOI: 10.1371/journal.pone.0161530</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Афанасьева О.И., Ежов М.В., Афанасьева М.И., Сафарова М.С., Берестецкая Ю.В., Покровский С.Н. Связь низкомолекулярного фенотипа апобелка(а) и концентрации липопротеида(а) с мультифокальным атеросклерозом у больных ишемической болезнью сердца. Рациональная фармакотерапия в кардиологии. 2010;6(4):474-80. DOI: 10.20996/1819-6446-2010-6-4-474-480</mixed-citation><mixed-citation xml:lang="en">Afanas'eva O.I., Ezhov M.V., Afanas'eva M.I., Safarova M.S., Berestetskaya Yu.V., Pokrovsky S.N. Correlations of low molecular weight phenotype of apoprotein(a) and serum level oflipoprotein(a) with multifocal atherosclerosis in patients with coronary heart disease. Rational Pharmacotherapy in Cardiology. 2010;6(4):474-80. DOI: 10.20996/1819-6446-2010-6-4-474-480</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Russian: Тмоян Н.А., Ежов М.В., Афанасьева О.И., Клесарева Е.А., Разова О.А., Кухарчук В.В., Покровский С.Н. Связь липопротеида(а) и фенотипов апобелка(а) со стенозирующим атеросклерозом периферических артерий. Терапевтический архив. 2018;90(9):31-6. DOI: 10.26442/terarkh201890931-36</mixed-citation><mixed-citation xml:lang="en">Tmoyan NA, Ezhov MV, Afanasieva OI, Klesareva EA, Razova OA, Kukharchuk VV et al. The association of lipoprotein(a) and apolipoprotein(a) phenotypes with peripheral artery disease. Therapeutic Archive. 2018;90(9):31-6. DOI: 10.26442/terarkh201890931-36</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">van Capelleveen JC, van der Valk FM, Stroes ESG. Current therapies for lowering lipoprotein (a). Journal of Lipid Research. 2016;57(9):1612-8. DOI: 10.1194/jlr.R053066</mixed-citation><mixed-citation xml:lang="en">van Capelleveen JC, van der Valk FM, Stroes ESG. Current therapies for lowering lipoprotein (a). Journal of Lipid Research. 2016;57(9):1612-8. DOI: 10.1194/jlr.R053066</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Rao F, Schork AJ, Maihofer AX, Nievergelt CM, Marcovina SM, Miller ER et al. Heritability of Biomarkers of Oxidized Lipoproteins: Twin Pair Study. Arteriosclerosis, Thrombosis, and Vascular Biology. 2015;35(7):1704-11. DOI: 10.1161/ATVBAHA.115.305306</mixed-citation><mixed-citation xml:lang="en">Rao F, Schork AJ, Maihofer AX, Nievergelt CM, Marcovina SM, Miller ER et al. Heritability of Biomarkers of Oxidized Lipoproteins: Twin Pair Study. Arteriosclerosis, Thrombosis, and Vascular Biology. 2015;35(7):1704-11. DOI: 10.1161/ATVBAHA.115.305306</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Tsimikas S, Willeit P, Willeit J, Santer P, Mayr M, Xu Q et al. Oxidation-Specific Biomarkers, Prospective 15-Year Cardiovascular and Stroke Outcomes, and Net Reclassification of Cardiovascular Events. Journal of the American College of Cardiology. 2012;60(21):2218-29. DOI: 10.1016/j.jacc.2012.08.979</mixed-citation><mixed-citation xml:lang="en">Tsimikas S, Willeit P, Willeit J, Santer P, Mayr M, Xu Q et al. Oxidation-Specific Biomarkers, Prospective 15-Year Cardiovascular and Stroke Outcomes, and Net Reclassification of Cardiovascular Events. Journal of the American College of Cardiology. 2012;60(21):2218-29. DOI: 10.1016/j.jacc.2012.08.979</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Miller YI, Choi S-H, Wiesner P, Fang L, Harkewicz R, Hartvigsen K et al. Oxidation-Specific Epitopes Are Danger-Associated Molecular Patterns Recognized by Pattern Recognition Receptors of Innate Immunity. Circulation Research. 2011;108(2):235-48. DOI: 10.1161/CIRCRESAHA.110.223875</mixed-citation><mixed-citation xml:lang="en">Miller YI, Choi S-H, Wiesner P, Fang L, Harkewicz R, Hartvigsen K et al. Oxidation-Specific Epitopes Are Danger-Associated Molecular Patterns Recognized by Pattern Recognition Receptors of Innate Immunity. Circulation Research. 2011;108(2):235-48. DOI: 10.1161/CIRCRESAHA.110.223875</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Menees SB, Powell C, Kurlander J, Goel A, Chey WD. A MetaAnalysis of the Utility of C-Reactive Protein, Erythrocyte Sedimentation Rate, Fecal Calprotectin, and Fecal Lactoferrin to Exclude Inflammatory Bowel Disease in Adults With IBS: American Journal of Gastroenterology. 2015;110(3):444-54. DOI: 10.1038/ajg.2015.6</mixed-citation><mixed-citation xml:lang="en">Menees SB, Powell C, Kurlander J, Goel A, Chey WD. A MetaAnalysis of the Utility of C-Reactive Protein, Erythrocyte Sedimentation Rate, Fecal Calprotectin, and Fecal Lactoferrin to Exclude Inflammatory Bowel Disease in Adults With IBS: American Journal of Gastroenterology. 2015;110(3):444-54. DOI: 10.1038/ajg.2015.6</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Ridker PM. A Test in Context: high-sensitivity C-reactive protein. Journal of the American College of Cardiology. 2016;67(6):712-23. DOI: 10.1016/j.jacc.2015.11.037</mixed-citation><mixed-citation xml:lang="en">Ridker PM. A Test in Context: high-sensitivity C-reactive protein. Journal of the American College of Cardiology. 2016;67(6):712-23.	DOI: 10.1016/j.jacc.2015.11.037</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Coffman E, Richmond-Bryant J. Multiple biomarker models for improved risk estimation of specific cardiovascular diseases related to metabolic syndrome: a cross-sectional study. Population Health Metrics. 2015;13(1):7. DOI: 10.1186/s12963-015-0041-5</mixed-citation><mixed-citation xml:lang="en">Coffman E, Richmond-Bryant J. Multiple biomarker models for improved risk estimation of specific cardiovascular diseases related to metabolic syndrome: a cross-sectional study. Population Health Metrics. 2015;13(1):7. DOI: 10.1186/s12963-015-0041-5</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Peng Y, Dong B, Wang Z. Overall and Gender-specific Associations between C-reactive Protein and Stroke Occurrence: A Crosssectional Study in US. Journal of Stroke. 2016;18(3):355-7. DOI: 10.5853/jos.2016.00451</mixed-citation><mixed-citation xml:lang="en">Peng Y, Dong B, Wang Z. Overall and Gender-specific Associations between C-reactive Protein and Stroke Occurrence: A Crosssectional Study in US. Journal of Stroke. 2016;18(3):355-7. DOI: 10.5853/jos.2016.00451</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Gong S, Gao X, Xu F, Shang Z, Li S, Chen W et al. Association of lymphocyte to monocyte ratio with severity of coronary artery disease: Medicine. 2018;97(43):e12813. DOI: 10.1097/MD.0000000000012813</mixed-citation><mixed-citation xml:lang="en">Gong S, Gao X, Xu F, Shang Z, Li S, Chen W et al. Association of lymphocyte to monocyte ratio with severity of coronary artery disease: Medicine. 2018;97(43):e12813. DOI: 10.1097/MD.0000000000012813</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
